Evidence map›Paper›PMID 17609392›Full record

ArticleClinical and vaccine immunology : CVI2007

Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C.

Gowrisankar Rajam, George M Carlone, Sandra Romero-Steiner

Abstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Microbiology spectrum · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.Advances in biochemical engineering/biotechnology · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. WciGJournal of clinical microbiology · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2016
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gowrisankar RajamDivision of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
George M Carlone
Sandra Romero-Steiner

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 23-valent pneumococcal polysaccharide (Ps) vaccine offer protection against vaccine serotypes, but its cross-protection against vaccine-related serotypes is variable. We have demonstrated that the functional antibodies to serotype 15B are specific to the O-acetylated 15B-Ps and that they have low cross-reactivity with serotype 15C. Demonstration of functionally cross-reactive antibodies to vaccine-related serotypes is important for surveillance and vaccine development.

Indexed as

AbsorptionAcetylationAntibodies, BacterialAntigen-Antibody ComplexCross ReactionsHumansPhagocytosisPneumococcal VaccinesSerotypingStreptococcus pneumoniae23-valent pneumococcal capsular polysaccharide vaccineAntibodies, BacterialAntigen-Antibody ComplexPneumococcal Vaccines

Identifiers

PMID17609392
PMCPMC2043308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.